Mechanical allodynia in mice with tenascin-X deficiency associated with Ehlers-Danlos syndrome.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 04 2020
16 04 2020
Historique:
received:
07
12
2019
accepted:
07
03
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
26
11
2020
Statut:
epublish
Résumé
Tenascin-X (TNX) is a member of the extracellular matrix glycoprotein tenascin family, and TNX deficiency leads to Ehlers-Danlos syndrome, a heritable human disorder characterized mostly by skin hyperextensibility, joint hypermobility, and easy bruising. TNX-deficient patients complain of chronic joint pain, myalgia, paresthesia, and axonal polyneuropathy. However, the molecular mechanisms by which TNX deficiency complicates pain are unknown. Here, we examined the nociceptive behavioral responses of TNX-deficient mice. Compared with wild-type mice, TNX-deficient mice exhibited mechanical allodynia but not thermal hyperalgesia. TNX deficiency also increased pain sensitivity to chemical stimuli and aggravated early inflammatory pain elicited by formalin. TNX-deficient mice were significantly hypersensitive to transcutaneous sine wave stimuli at frequencies of 250 Hz (Aδ fiber responses) and 2000 Hz (Aβ fiber responses), but not to stimuli at frequency of 5 Hz (C fiber responses). In addition, the phosphorylation levels of extracellular signal-related kinase, an active neuronal marker, and the activity of NADPH-diaphorase, a neuronal nitric oxide activation marker, were enhanced in the spinal dorsal horns of TNX-deficient mice. These results suggest that TNX deficiency contributes to the development of mechanical allodynia and hypersensitivity to chemical stimuli, and it induces hypersensitization of myelinated A fibers and activation of the spinal dorsal horn.
Identifiants
pubmed: 32300146
doi: 10.1038/s41598-020-63499-2
pii: 10.1038/s41598-020-63499-2
pmc: PMC7162960
doi:
Substances chimiques
Analgesics
0
RNA, Messenger
0
Tenascin
0
tenascin X
0
Formaldehyde
1HG84L3525
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6569Références
Bristow, J., Carey, W., Egging, D. & Schalkwijk, J. Tenascin-X, collagen, elastiin, and the Ehlers-Danlos Syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 139C, 24–30 (2005).
doi: 10.1002/ajmg.c.30071
Burch, G. H. et al. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat. Genet. 17, 104–108 (1997).
pubmed: 9288108
doi: 10.1038/ng0997-104
pmcid: 9288108
Demirdas, S. et al. Recognizing the tenascin-X deficient type of Ehlers-Danlos syndrome: a cross-sectional study in 17 patients. Clin. Genet. 91, 411–425 (2017).
pubmed: 27582382
doi: 10.1111/cge.12853
pmcid: 27582382
Schalkwijk, J. et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N. Engl. J. Med. 345, 1167–1175 (2001).
pubmed: 11642233
doi: 10.1056/NEJMoa002939
pmcid: 11642233
Voermans., N. C. et al. Neuromuscular involvement in various types of Ehlers-Danlos syndrome. Ann. Neurol. 65, 687–697 (2009).
pubmed: 19557868
doi: 10.1002/ana.21643
pmcid: 19557868
Malfait, F. et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am. J. Med. Genet. C Semin. Med. Genet. 175, 8–26 (2017).
pubmed: 28306229
doi: 10.1002/ajmg.c.31552
pmcid: 28306229
Mao, J. R. et al. Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat. Genet. 30, 421–425 (2002).
pubmed: 11925569
doi: 10.1038/ng850
pmcid: 11925569
Minamitani, T. et al. Modulation of collagen fibrillogenesis by tenascin-X and type VI collagen. Exp. Cell Res. 298, 305–315 (2004).
pubmed: 15242785
doi: 10.1016/j.yexcr.2004.04.030
pmcid: 15242785
Chopra, P. et al. Pain management in the Ehlers-Danlos syndromes. Am. J. Med. Genet. C Semin. Med. Genet. 175, 212–219 (2017).
pubmed: 28186390
doi: 10.1002/ajmg.c.31554
pmcid: 28186390
Syx., D., De Wandele, I., Rombaut, L. & Malfait, F. Hypermobility, the Ehlers-Danlos syndromes and chronic pain. Clin. Exp. Rheumatol. 107, 116–122 (2017).
Voermans, N. C., Knoop, H., Bleijenberg, G. & van Engelen, B. G. Pain in ehlers-danlos syndrome is common, severe, and associated with functional impairment. J. Pain Symptom. Manage. 40, 370–378 (2010).
pubmed: 20579833
doi: 10.1016/j.jpainsymman.2009.12.026
pmcid: 20579833
Stoler, J. M. & Oaklander, A. L. Patients with Ehlers Danlos syndrome and CRPS: a possible association? Pain 123, 204–209 (2006).
pubmed: 16600507
doi: 10.1016/j.pain.2006.02.022
pmcid: 16600507
Di Stefano, G. et al. Central sensitization as the mechanism underlying pain in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Eur. J. Pain 20, 1319–1325 (2016).
pubmed: 26919608
doi: 10.1002/ejp.856
pmcid: 26919608
Rombaut, L. et al. Impairment and impact of pain in female patients with Ehlers-Danlos syndrome: a comparative study with fibromyalgia and rheumatoid arthritis. Arthritis. Rheum. 63, 1979–1987 (2011).
pubmed: 21391202
doi: 10.1002/art.30337
pmcid: 21391202
Rodgers, K. R., Gui, J., Dinulos, M. B. & Chou, R. C. Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. Sci. Rep. 7, 39636, https://doi.org/10.1038/srep39636 (2017).
doi: 10.1038/srep39636
pubmed: 28051109
pmcid: 5209734
Tjolsen, A., Berge, O. G., Hunskaar, S., Rosland, J. H. & Hole, K. The formalin test: an evaluation of the method. Pain 51, 5–17 (1992).
pubmed: 1454405
doi: 10.1016/0304-3959(92)90003-T
pmcid: 1454405
Alles, S. R. A. & Smith, P. A. Etiology and pharmacology of neuropathic pain. Pharmacol. Review. 70, 315–347 (2018).
doi: 10.1124/pr.117.014399
Minami, T. et al. Functional evidence for interaction between prostaglandin EP3 and κ-opioid receptor pathways in tactile pain induced by human immunodeficiency virus type-1 (HIV-1) glycoprotein gp120. Neuropharamacol. 45, 96–105 (2003).
doi: 10.1016/S0028-3908(03)00133-3
Duan, B., Cheng, L. & Ma, Q. Spinal Circuits Transmitting Mechanical Pain and Itch. Neurosci. Bull. 34, 186–93 (2018).
pubmed: 28484964
doi: 10.1007/s12264-017-0136-z
pmcid: 28484964
Moehring, F., Halder, P., Seal, R. P. & Stucky, C. L. Uncovering the Cells and Circuits of Touch in Normal and Pathological Settings. Neuron 100, 349–360 (2018).
pubmed: 30359601
pmcid: 6708582
doi: 10.1016/j.neuron.2018.10.019
Katims, J. J. Neuroselective current perception threshold quantitative sensory test. Muscle Nerve 20, 1468–1469 (1997).
pubmed: 9342169
doi: 10.1002/(SICI)1097-4598(199711)20:11<1468::AID-MUS21>3.0.CO;2-X
pmcid: 9342169
Koga, K. et al. Selective activation of primary afferent fibers evaluated by sin-wave electrical atimulation. Mol. Pain 1, 13, https://doi.org/10.1186/1744-8069-1-13 (2005).
doi: 10.1186/1744-8069-1-13
pubmed: 15813963
pmcid: 1083421
Ito, S., Okuda-Ashitaka, E. & Minami, T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci. Res. 41, 299–332 (2001).
pubmed: 11755218
doi: 10.1016/S0168-0102(01)00289-9
pmcid: 11755218
Dawson, T. M., Bredt, D. S., Fotuhi, M., Hwang, P. M. & Snyder, S. H. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc. Natl. Acad. Sci. USA 88, 7797–7801 (1991).
pubmed: 1715581
doi: 10.1073/pnas.88.17.7797
pmcid: 1715581
LaBuda, C. J. & Little, P. J. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J. Neurosci. Methods 144, 175–181 (2005).
pubmed: 15910975
doi: 10.1016/j.jneumeth.2004.11.008
pmcid: 15910975
Salinas-Abarca, A. B., Avila-Rojas, A. H., Barragán-Iglesias, P., Pineda-Farias, J. B. & Granados-Soto, V. Formalin injection produces long-lasting hypersensitivity with characteristics of neuropathic pain. Eur. J. Pharamacol. 797, 83–93 (2017).
doi: 10.1016/j.ejphar.2017.01.018
Kohno, T. et al. Peripheral axonal injury results in reduced µ opiod receptor pre- and post-synaptic action in the spinal cord. Pain 117, 77–87 (2005).
pubmed: 16098668
doi: 10.1016/j.pain.2005.05.035
pmcid: 16098668
Halder, S. K., Yano, R., Chun, J. & Ueda, H. Involvement of LPA1 receptor signaling in cerebral ischemia-induced neuropathic pain. Neuroscience 235, 10–15 (2013).
pubmed: 23318243
doi: 10.1016/j.neuroscience.2013.01.005
pmcid: 23318243
Matsumoto, M., Inoue, M., Hald, A., Yamaguch, A. & Ueda, H. Characterization of three different sensory fibers by use of neonatal capsaicin treatment, spinal antagonism and a novel electrical stimulation-induced paw flexion test. Mol. Pain 2, 16, https://doi.org/10.1186/1744-8069-2-16 (2006).
doi: 10.1186/1744-8069-2-16
pubmed: 16681855
pmcid: 1482679
Minami, T. et al. Characterization of nociceptin/orphanin FQ-induced pain responses in conscious mice: neonatal capsaicin treatment and N-methyl-D-aspartate receptor GluRε subunit knockout mice. Neuroscience 97, 133–142 (2000).
pubmed: 10771345
doi: 10.1016/S0306-4522(00)00010-5
pmcid: 10771345
Matsumoto, M., Inoue, M., Hald, A., Weijiao, X. & Ueda, H. Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J. Pharmacol. Exp. Ther. 318, 735–740 (2006).
pubmed: 16687474
doi: 10.1124/jpet.106.103614
pmcid: 16687474
Ikoma, M., Kohno, T. & Baba, H. Differential presynaptic effects of opioid agonists on Aδ- and C-afferent glutamatergic transmission to the spinal dorsal horn. Anesthesiology 107, 807–812 (2007).
pubmed: 18073556
doi: 10.1097/01.anes.0000286985.80301.5e
pmcid: 18073556
Heinke, B., Gingl, E. & Sandkühler, J. Multiple targets of μ-opioid receptor-mediated presynaptic inhibition at primary afferent Aδ- and C- fibers. J. Neurosci. 31, 1313–1322 (2011).
pubmed: 21273416
pmcid: 6623607
doi: 10.1523/JNEUROSCI.4060-10.2011
Puig, S. & Sorkin, L. S. Formalin-evoked activity in identified primary afferent fibers: ayatemic lidocaine suppresses phase-2 activity. Pain 64, 345–355 (1995).
doi: 10.1016/0304-3959(95)00121-2
McNamara, C. R. et al. TRPA1 mediates formalin-induced pain. Proc. Natl. Acad. Sci. USA 104, 13525–13530 (2007).
pubmed: 17686976
doi: 10.1073/pnas.0705924104
pmcid: 17686976
Aktar, R. et al. The extracellular matrix glycoprotein tenascin-X regulates peripheral sensory and motor neurones. J. Physiol. 596, 4237–4251 (2018).
pubmed: 29917237
pmcid: 6117562
doi: 10.1113/JP276300
Sakai, H. et al. A potential contribution of tenascin-X to blood vessel formation in peripheral nerves. Neurosci. Res. 124, 1–7 (2017).
pubmed: 28668501
doi: 10.1016/j.neures.2017.06.003
Voermans, N. C. et al. Mild muscular features in tenascin-X knockout mice, a model of Ehlers-danlos syndrome. Connect Tissue Res. 52, 422–432 (2011).
pubmed: 21405982
doi: 10.3109/03008207.2010.551616
Matsumoto, K. I. et al. Distribution of extracellular matrix tenascin-X in sciatic nerves. Acta. Neuropathol. 104, 448–454 (2002).
pubmed: 12410392
doi: 10.1007/s00401-002-0577-x
Wei, Z., Fei, Y., Su, W. & Chen, G. Emerging Role of Schwann Cells in Neuropathic Pain: Receptors, Glial Mediators and Myelination. Front. Cell Neurosci. 13, 116, https://doi.org/10.3389/fncel.2019.00116 (2019).
doi: 10.3389/fncel.2019.00116
pubmed: 30971897
pmcid: 6445947
Ueda, H. Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination. Mol. Pain 4, 11, https://doi.org/10.1186/1744-8069-4-11 (2008).
doi: 10.1186/1744-8069-4-11
pubmed: 18377664
pmcid: 2365930
Deckner, M., Lindholm, T., Cullheim, S. & Risling, M. Differential expression of tenascin-C, tenascin-R, tenascin/J1, and tenascin-X in spinal cord scar tissue and in the olfactory system. Exp. Neurol. 166, 350–362 (2000).
pubmed: 11085900
doi: 10.1006/exnr.2000.7543
pmcid: 11085900
Imura, K. & Sato, I. Novel localization of tenascin-X in adult mouse leptomeninges and choroid plexus. Ann. Anat. 190, 324–328 (2008).
pubmed: 18595676
doi: 10.1016/j.aanat.2008.04.003
pmcid: 18595676
Weller, R. O., Sharp, M. M., Christodoulides, M., Carare, R. O. & Mollgard, K. The meninges as barriers and facilitators for the movement of fluid, cells and pathogens related to the rodent and human CNS. Acta. Neuropathol. 135, 363–385 (2018).
pubmed: 29368214
doi: 10.1007/s00401-018-1809-z
pmcid: 29368214
Du, B. et al. CD4+ αβ T cell infiltration into the leptomeninges of lumbar dorsal roots contributes to the transition from acute to chronic mechanical allodynia after adult rat tibial nerve injuries. J. Neuroinflammation 15, 81, https://doi.org/10.1186/s12974-018-1115-7 (2018).
doi: 10.1186/s12974-018-1115-7
pubmed: 29544518
pmcid: 5855984
Matsumoto, K. I. et al. Tumour invasion and metastasis are promoted in mice deficient in tenascin-X. Genes Cells 6, 1101–1111 (2001).
pubmed: 11737270
doi: 10.1046/j.1365-2443.2001.00482.x
pmcid: 11737270
Okamoto, K. et al. Involvement of NIPSNAP1, a neuropeptide nocistatin-interacting protein, in inflammatory pain. Mol. Pain 12, 1–11, https://doi.org/10.1177/1744806916637699 (2016).
doi: 10.1177/1744806916637699
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–63 (1994).
pubmed: 7990513
doi: 10.1016/0165-0270(94)90144-9
pmcid: 7990513
Garrison, S. R., Dietrich, A. & Stucky, C. L. TRPC1 contributes to light-touch sensation and mechanical responses in low-threshold cutaneous sensory neurons. J. Neurophysiol. 107, 913–922 (2012).
pubmed: 22072513
doi: 10.1152/jn.00658.2011
pmcid: 22072513
Okuda-Ashitaka, E. et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 392, 286–289 (1998).
pubmed: 9521323
doi: 10.1038/32660
pmcid: 9521323
Tsuda, M. et al. Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays. Mol. Pain 5, 28, https://doi.org/10.1186/1744-8069-5-28 (2009).
doi: 10.1186/1744-8069-5-28
pubmed: 19515262
pmcid: 2704200
Nakano, H. et al. Effect of intrathecal nocistatin on the formalin-induced pain in mice versus that of nociceptin/orphanin FQ. J. Pharmaco.l Exp. Ther. 292, 331–336 (2000).
Hylden, J. K. & Wilcox, G. L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 67, 313–316 (1980).
pubmed: 6893963
doi: 10.1016/0014-2999(80)90515-4
pmcid: 6893963
Mabuchi, T. et al. Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production. Eur. J. Neurosci. 17, 1384–1392 (2003).
pubmed: 12713641
doi: 10.1046/j.1460-9568.2003.02575.x
pmcid: 12713641